Cargando…
Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers
BACKGROUND: Chemokines, including chemokine (C-X-C motif) ligand 1 (CXCL1), may regulate tumor epithelial-stromal interactions that facilitate tumor growth and invasion. Studies have linked CXCL1 expression to gastric, colon and skin cancers, but limited studies to date have described CXCL1 protein...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708804/ https://www.ncbi.nlm.nih.gov/pubmed/23815949 http://dx.doi.org/10.1186/1471-2407-13-322 |
_version_ | 1782276662767910912 |
---|---|
author | Miyake, Makito Lawton, Adrienne Goodison, Steve Urquidi, Virginia Gomes-Giacoia, Evan Zhang, Ge Ross, Shanti Kim, Jeongsoon Rosser, Charles J |
author_facet | Miyake, Makito Lawton, Adrienne Goodison, Steve Urquidi, Virginia Gomes-Giacoia, Evan Zhang, Ge Ross, Shanti Kim, Jeongsoon Rosser, Charles J |
author_sort | Miyake, Makito |
collection | PubMed |
description | BACKGROUND: Chemokines, including chemokine (C-X-C motif) ligand 1 (CXCL1), may regulate tumor epithelial-stromal interactions that facilitate tumor growth and invasion. Studies have linked CXCL1 expression to gastric, colon and skin cancers, but limited studies to date have described CXCL1 protein expression in human bladder cancer (BCa). METHODS: CXCL1 protein expression was examined in 152 bladder tissue specimens (142 BCa) by immunohistochemical staining. The expression of CXCL1 was scored by assigning a combined score based on the proportion of cells staining and intensity of staining. CXCL1 expression patterns were correlated with clinicopathological features and follow-up data. RESULTS: CXCL1 protein expression was present in cancerous tissues, but was entirely absent in benign tissue. CXCL1 combined immunostaining score was significantly higher in high-grade tumors relative to low-grade tumors (p = 0.012). Similarly, CXCL1 combined immunostaining score was higher in high stage tumors (T2-T4) than in low stage tumors (Ta-T1) (p < 0.0001). An increase in the combined immunostaining score of CXCL1 was also associated with reduced disease-specific survival. CONCLUSION: To date, this is the largest study describing increased CXCL1 protein expression in more aggressive phenotypes in human BCa. Further studies are warranted to define the role CXCL1 plays in bladder carcinogenesis and progression. |
format | Online Article Text |
id | pubmed-3708804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37088042013-07-12 Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers Miyake, Makito Lawton, Adrienne Goodison, Steve Urquidi, Virginia Gomes-Giacoia, Evan Zhang, Ge Ross, Shanti Kim, Jeongsoon Rosser, Charles J BMC Cancer Research Article BACKGROUND: Chemokines, including chemokine (C-X-C motif) ligand 1 (CXCL1), may regulate tumor epithelial-stromal interactions that facilitate tumor growth and invasion. Studies have linked CXCL1 expression to gastric, colon and skin cancers, but limited studies to date have described CXCL1 protein expression in human bladder cancer (BCa). METHODS: CXCL1 protein expression was examined in 152 bladder tissue specimens (142 BCa) by immunohistochemical staining. The expression of CXCL1 was scored by assigning a combined score based on the proportion of cells staining and intensity of staining. CXCL1 expression patterns were correlated with clinicopathological features and follow-up data. RESULTS: CXCL1 protein expression was present in cancerous tissues, but was entirely absent in benign tissue. CXCL1 combined immunostaining score was significantly higher in high-grade tumors relative to low-grade tumors (p = 0.012). Similarly, CXCL1 combined immunostaining score was higher in high stage tumors (T2-T4) than in low stage tumors (Ta-T1) (p < 0.0001). An increase in the combined immunostaining score of CXCL1 was also associated with reduced disease-specific survival. CONCLUSION: To date, this is the largest study describing increased CXCL1 protein expression in more aggressive phenotypes in human BCa. Further studies are warranted to define the role CXCL1 plays in bladder carcinogenesis and progression. BioMed Central 2013-07-01 /pmc/articles/PMC3708804/ /pubmed/23815949 http://dx.doi.org/10.1186/1471-2407-13-322 Text en Copyright © 2013 Miyake et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Miyake, Makito Lawton, Adrienne Goodison, Steve Urquidi, Virginia Gomes-Giacoia, Evan Zhang, Ge Ross, Shanti Kim, Jeongsoon Rosser, Charles J Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers |
title | Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers |
title_full | Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers |
title_fullStr | Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers |
title_full_unstemmed | Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers |
title_short | Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers |
title_sort | chemokine (c-x-c) ligand 1 (cxcl1) protein expression is increased in aggressive bladder cancers |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708804/ https://www.ncbi.nlm.nih.gov/pubmed/23815949 http://dx.doi.org/10.1186/1471-2407-13-322 |
work_keys_str_mv | AT miyakemakito chemokinecxcligand1cxcl1proteinexpressionisincreasedinaggressivebladdercancers AT lawtonadrienne chemokinecxcligand1cxcl1proteinexpressionisincreasedinaggressivebladdercancers AT goodisonsteve chemokinecxcligand1cxcl1proteinexpressionisincreasedinaggressivebladdercancers AT urquidivirginia chemokinecxcligand1cxcl1proteinexpressionisincreasedinaggressivebladdercancers AT gomesgiacoiaevan chemokinecxcligand1cxcl1proteinexpressionisincreasedinaggressivebladdercancers AT zhangge chemokinecxcligand1cxcl1proteinexpressionisincreasedinaggressivebladdercancers AT rossshanti chemokinecxcligand1cxcl1proteinexpressionisincreasedinaggressivebladdercancers AT kimjeongsoon chemokinecxcligand1cxcl1proteinexpressionisincreasedinaggressivebladdercancers AT rossercharlesj chemokinecxcligand1cxcl1proteinexpressionisincreasedinaggressivebladdercancers |